Protein S Deficiency: Comprehensive Research Report

1. Disease Information

Overview. Protein S deficiency is an inherited or acquired thrombophilia caused by reduced plasma levels or functional activity of protein S, a vitamin K–dependent plasma glycoprotein that acts as a non-enzymatic cofactor for the anticoagulant proteins activated protein C (APC) and tissue factor pathway inhibitor (TFPI). Deficiency impairs down-regulation of the coagulation cascade, producing a hypercoagulable state manifesting predominantly as venous thromboembolism (VTE) — deep vein thrombosis (DVT), pulmonary embolism (PE), and superficial thrombophlebitis. A rare, severe homozygous/compound-heterozygous form causes neonatal purpura fulminans, a life-threatening disseminated microvascular thrombosis syndrome (StatPearls, NCBI Bookshelf NBK544344).

Key identifiers: - OMIM (gene): 176880 — PROS1 (protein S) - OMIM (phenotype, autosomal dominant/heterozygous): #612336 — Thrombophilia due to Protein S Deficiency, Autosomal Dominant (THPH5) (OMIM 612336) - OMIM (phenotype, autosomal recessive/severe): #614514 — Thrombophilia due to Protein S Deficiency, Autosomal Recessive (THPH6) (OMIM 614514) - Orphanet: ORPHA:743 — Severe hereditary thrombophilia due to congenital protein S deficiency (Orphanet 743) - MONDO: MONDO:0002304 - Disease Ontology: DOID:2451 - HPO (phenotype term): HP:0004855 (Protein S deficiency) - ICD-10-CM: D68.59 (Other primary thrombophilia — used for hereditary protein S deficiency) - Gene locus:* PROS1, chromosome 3q11.1 (HGNC:9457)

Synonyms: PS deficiency; hereditary/congenital protein S deficiency; THPH5 (dominant form); THPH6 (recessive/severe form); "protein S Tokushima" for the Japanese K155E/K196E variant designation.

Evidence base note: Much of the epidemiological and clinical literature derives from aggregated case-series, thrombophilia-clinic cohorts, and family/kindred studies rather than large population-representative EHR datasets — an important caveat given the assay/pre-analytical variability discussed in Section 10.

2. Etiology

Causal factors

Protein S deficiency arises from two broad mechanisms:

Congenital (genetic): Heterozygous or homozygous/compound-heterozygous pathogenic variants in PROS1. Over 200–300+ distinct PROS1 mutations have been catalogued (StatPearls cites >200; other reviews cite >300), including missense variants (most common), nonsense variants, small insertions/deletions, splice-site variants, and large deletions spanning one or multiple exons (ClinVar Miner; Human Genome Variation 2024). Most loss-of-function mutations produce premature stop codons and truncated, non-secreted or non-functional protein.
Acquired: Reduced protein S levels/activity secondary to another physiologic or pathologic state — vitamin K antagonist (warfarin) therapy, vitamin K deficiency, liver disease, nephrotic syndrome (urinary protein loss), disseminated intravascular coagulation (DIC), pregnancy, oral contraceptive/estrogen or hormone-replacement therapy, systemic lupus erythematosus, HIV infection, chronic/acute infection, and myeloproliferative disorders (StatPearls; Medscape overview).

Genetic risk factors

Causal PROS1 variants — dominant heterozygous variants cause the common, milder Type I/III phenotype; biallelic (homozygous or compound heterozygous) variants cause the severe neonatal form.
Founder/population-specific variant: PROS1 c.586A>G (p.Lys196Glu, "K196E"/legacy "K155E," known as "protein S Tokushima") is essentially restricted to Japanese populations, present in ~1.8% of Japanese individuals, and confers an odds ratio of 3.7–8.6 for VTE; it has not been found in Chinese, Korean, or Caucasian populations (racial-differences PMC7695562; PLOS ONE 2015).
Combined/modifier genetic factors: Co-inheritance of Factor V Leiden (FVL) with PROS1 deficiency is well documented and synergistically increases thrombosis risk (see Section 9).

Environmental / acquired risk factors

Immobility, surgery, trauma, pregnancy/puerperium, estrogen-containing contraceptives or HRT, and long-haul travel are documented precipitants; a large kindred study found that although these factors were common, "almost half of the events were spontaneous" (ClinVar/OMIM search summary; Annals of Internal Medicine 1998).

Protective factors

No specific genetic or environmental protective variant/exposure for protein S deficiency was identified in the literature searched; general VTE risk-reduction measures (avoidance of estrogen therapy, maintaining mobility, prophylactic anticoagulation during high-risk periods) apply, but the review found no dedicated protective-allele literature analogous to, e.g., Factor V Leiden's population-genetics protective hypotheses.

Gene–environment interaction

The clearest documented interaction is with exogenous estrogen (oral contraceptives, HRT, pregnancy), which itself lowers free protein S levels physiologically and is superimposed on a genetically reduced baseline, precipitating clinical thrombosis in previously asymptomatic carriers ("Protein S levels decrease in pregnancy and can fall into the abnormal-low laboratory range" — Cleveland Clinic; StatPearls).

3. Phenotypes

Phenotype categories and suggested HPO terms

Table (click to expand)

Phenotype	Type	Suggested HPO term
Deep vein thrombosis	Sign/laboratory-imaging	HP:0002625 (Peripheral thrombosis) / HP:0004936 (Deep venous thrombosis, if available)
Pulmonary embolism	Sign	HP:0004942 (Pulmonary embolism)
Superficial thrombophlebitis	Sign	HP:0025138 (Phlebitis) or related
Purpura fulminans (neonatal)	Sign, severe/congenital	HP:0025282 (Purpura fulminans)
Recurrent pregnancy loss	Sign	HP:0032449 (Recurrent miscarriage)
Cerebral venous sinus thrombosis	Sign, rare-site	HP:0006956 (Cerebral venous thrombosis, if modeled)
Reduced Protein S activity/antigen	Laboratory abnormality	HP:0004855 (Protein S deficiency)
Warfarin-induced skin necrosis	Sign, treatment complication	(no direct HP term; model as adverse-drug-reaction phenotype)
Post-thrombotic syndrome	Sign, sequela	HP:0025490 (if modeled)

Characteristics

Onset: Two clearly separable onset patterns —
Heterozygous/mild congenital or acquired disease: adult-onset, with median age at first VTE around 29 years in some cohorts; "almost half of all individuals with protein S deficiency become symptomatic before age 55" (StatPearls).
Homozygous/compound heterozygous severe disease: neonatal onset, "manifests several hours to days after birth, with purpura fulminans or massive venous thrombosis" (NORD/GARD).
Severity: Highly variable in the heterozygous form (many carriers remain asymptomatic lifelong — see penetrance below); uniformly severe and life-threatening in the biallelic neonatal form.
Progression: Recurrent/relapsing pattern typical for heterozygous VTE; the neonatal form is acute and rapidly progressive without emergency plasma replacement.
Frequency of specific manifestations among symptomatic patients: DVT ~74%, superficial thrombophlebitis ~72%, PE ~38% (may co-occur); "venous thromboembolism occurring in approximately 50–60% of people with protein S deficiency" who are carriers over their lifetime; involvement of cerebral, visceral, mesenteric, or axillary veins is comparatively rare (Cleveland Clinic; StatPearls).
Penetrance: Among heterozygous carriers, roughly 50% develop venous thromboembolism in their lifetime; 50% remain asymptomatic (StatPearls).
Quality of life impact: Not extensively quantified in disease-specific QOL instruments in the literature surveyed; morbidity relates chiefly to recurrent VTE, post-thrombotic syndrome, chronic anticoagulation burden/bleeding risk, and (in severe cases) neurodevelopmental sequelae from neonatal thrombosis/hemorrhage (e.g., a reported case with in utero retinal vessel thrombosis and blindness — OMIM 614514).

4. Genetic / Molecular Information

Causal gene

PROS1 (Protein S), HGNC:9457, chromosome 3q11.1. OMIM *176880.

Variant classification and types

Type of variants: predominantly missense; also nonsense, small indels, splice-site, and large exonic deletions (ClinVar Miner).
A 2024–2025 systematic reanalysis of 276 patients with suspected hereditary PS deficiency identified 48 distinct variants across 101 patients — 27 previously reported, 11 present in ClinVar/dbSNP without prior clinical categorization, and 10 entirely novel (PubMed 42079676).
Specific examples: p.Thr78Met (ClinVar RCV000197958), p.Met640Thr (RCV001211450), p.Arg355Cys (RCV000022724), p.Ser501Pro (RCV000205145), p.Val606Ile (RCV000206212), p.Leu584Arg (mesenteric/portal vein thrombosis case, PMC10682651), and c.602-2delA (splice acceptor mutation, exon 7, in a Polish VTE patient, PMC7558706).
A stop-codon read-through variant (wobble-position A→T transversion) extends the protein by 14 amino acids before reaching a novel stop codon, illustrating an unusual loss-of-function mechanism.
Founder variant: PROS1 c.586A>G p.Lys196Glu ("K196E"/"K155E," "PS Tokushima") — Japan-specific, ~1.8% allele carriage, associated with Type II-pattern deficiency (normal antigen, reduced APC-cofactor functional activity) (ClinVar RCV000014246; PMC6178719).

Functional consequence / laboratory classification (ISTH system)

Three recognized subtypes, based on total antigen, free antigen, and functional (cofactor) activity: - Type I: ↓ total protein S antigen, ↓ free antigen, ↓ activity (quantitative deficiency). - Type II: normal antigen levels (total and free), ↓ functional activity (qualitative/dysfunctional protein — e.g., K196E "PS Tokushima"). - Type III: normal total antigen, ↓ free antigen, ↓ activity (abnormal partitioning between free and C4BP-bound forms). Type II is rare; Types I and III are the most common phenotypes clinically encountered (StatPearls).

Modifier genes

Factor V Leiden (F5 R506Q) — most clinically significant co-inherited modifier; markedly amplifies thrombotic risk when combined with PROS1 deficiency (Section 9).

Population allele frequency

Founder K196E variant carrier frequency ~1.8% in Japan (estimated ~9,440 individuals homozygous in the Japanese population) (PLOS ONE).
General-population heterozygous ("partial") deficiency prevalence: 0.16–0.21% (Orphanet); blood-donor cohort estimates 0.03–0.13%, rising to 3–5% among patients selected for recurrent thrombosis/strong family history (StatPearls).

Epigenetics / chromosomal abnormalities

No disease-specific epigenetic mechanism (DNA methylation/histone modification) or recurrent chromosomal structural abnormality was found reported for PROS1-related deficiency in the literature surveyed; the genetic architecture is single-gene Mendelian (with digenic/oligogenic modification by FVL).

5. Environmental Information

Pharmacologic/hormonal exposures: Vitamin K antagonists (warfarin) directly suppress synthesis of functional (carboxylated) protein S; estrogen-containing oral contraceptives, hormone replacement therapy, and pregnancy physiologically lower free protein S and unmask latent deficiency (Cleveland Clinic).
Nutritional/vitamin status: Vitamin K deficiency (malabsorption, dietary insufficiency, antibiotic-associated) reduces γ-carboxylation of protein S, lowering functional activity.
Hepatic and renal disease: Liver disease reduces synthetic production; nephrotic syndrome causes urinary loss of protein S (a smaller, more easily lost molecule relative to some other coagulation factors).
Infectious/inflammatory triggers: Acute infection and DIC consume and lower protein S acutely; chronic infections (e.g., HIV) are associated with acquired deficiency.
Autoimmune disease: Systemic lupus erythematosus is associated with acquired protein S deficiency, sometimes compounded by antiphospholipid antibodies.
No specific infectious pathogen causally produces the inherited disorder; infection functions as an acquired-deficiency trigger and precipitant of thrombosis, not an etiological agent of the genetic disease itself.

6. Mechanism / Pathophysiology

Ordered causal chain

A heterozygous (or homozygous/compound heterozygous) loss-of-function variant in PROS1 → reduced synthesis, secretion, or functional activity of protein S in hepatocytes and (to a lesser extent) endothelial cells and megakaryocytes.
Reduced circulating free/functional protein S → diminished APC-cofactor activity, because protein S normally accelerates activated protein C (APC)-mediated proteolytic inactivation of factors Va and VIIIa by roughly 10-fold (a γ-carboxyglutamic-acid–dependent function requiring the Gla domain) (ASH Blood 2011).
In parallel, reduced protein S → diminished TFPIα cofactor function: the Laminin-G1 (LG1) domain of protein S binds TFPIα's K3 domain and enhances TFPIα-mediated inhibition of factor Xa 4- to 10-fold by promoting TFPIα association with phospholipid membrane surfaces (AHA journals ATVB 2008; Science Advances 2024). A 2024 in vivo study found "TFPIα anticoagulant function is highly dependent on protein S in vivo," underscoring this as a major, independent (APC-free) anticoagulant pathway.
Loss of these two cofactor functions, plus loss of protein S's direct inhibition of the intrinsic tenase (FVIIIa–FIXa) and prothrombinase (FVa–FXa) complexes, leads to failure to down-regulate thrombin generation, particularly at sites of vascular injury.
Unchecked thrombin generation → excess fibrin formation and platelet activation, tipping local hemostatic balance toward pathological clot formation → venous thrombus formation (most often in the deep veins of the lower extremity).
A propagating or embolizing thrombus → pulmonary embolism, or (in unusual/high-risk sites) cerebral venous sinus, mesenteric, portal, or axillary vein thrombosis.
In the rare biallelic/severe form, near-total absence of protein S (plasma levels <1% reported in purpura-fulminans infants) → diffuse microvascular thrombosis in skin and viscera within hours to days of birth, producing purpura fulminans, DIC, and in some cases intracranial hemorrhage or in-utero ocular vascular thrombosis causing blindness (OMIM 614514; PubMed 2231208).
Branch — Warfarin-induced skin necrosis: in a protein-deficient patient started on warfarin without heparin bridging, the drug's early, more rapid suppression of already-low protein C/protein S relative to slower-acting procoagulant factor depletion transiently amplifies the pre-existing procoagulant tilt → microvascular thrombosis in skin/subcutaneous fat, producing painful purpuric/necrotic skin lesions; this is a recognized (though for protein S specifically, less common than for protein C deficiency) risk. ("Warfarin-induced skin necrosis has been associated with protein C deficiency but only rarely reported in patients with a deficiency of protein S" — PubMed 1427456; PubMed 9885367).
Branch — Combined defect amplification: co-inheritance of Factor V Leiden (which itself impairs APC-mediated FVa inactivation) with protein S deficiency compounds the loss of APC-pathway regulation through two independent mechanisms simultaneously, synergistically (not merely additively) raising thrombotic risk (Section 9) — a demonstrated "two-hit" model.

Molecular pathways

KEGG/Reactome-relevant pathways: Complement and coagulation cascades (KEGG hsa04610); Regulation of Complement cascade / Protein C activation; Formation of Fibrin Clot (Clotting Cascade) in Reactome; the APC-Protein S and TFPI-Protein S anticoagulant sub-pathways.

Protein structure/dysfunction

Protein S is a multidomain, vitamin K–dependent glycoprotein comprising: - An N-terminal Gla domain (10 γ-carboxyglutamic acid residues, vitamin K–dependently modified — required for phospholipid membrane binding and, notably, for APC-cofactor activity via a specific Gla residue) (ASH Blood 2011). - A thrombin-sensitive region (TSR). - Four tandem EGF-like domains. - A C-terminal SHBG-like domain containing two Laminin G-type (LG1, LG2) domains, together constituting >55% of the mature protein's length; the LG1 domain mediates TFPIα cofactor activity and is competitively regulated by C4BP binding, while the first LG domain also binds/activates the receptor tyrosine kinase Tyro3 for non-hemostatic (efferocytosis/immune) signaling (Blood Advances 2022; ScienceDirect 2022). - C4b-binding protein (C4BP) partitioning: ~60–70% of circulating protein S is bound in a high-affinity 1:1 complex with the C4BP β-chain (via both LG domains) and is anticoagulantly inactive; only the ~30–40% free fraction is functionally active as an APC/TFPI cofactor. This is the molecular basis of Type III deficiency, in which free-fraction partitioning is abnormal despite normal total antigen.

Cellular processes / tissue-level consequences

Endothelial dysfunction and loss of local anticoagulant surface regulation at sites of venous stasis/injury; downstream fibrin deposition and, in purpura fulminans, dermal/subcutaneous ischemic necrosis from occlusive microvascular thrombosis.

Advanced/omics findings

The literature reviewed did not surface disease-specific transcriptomic, proteomic, or single-cell datasets specific to PROS1 deficiency beyond conventional coagulation-assay and genetic-variant characterization; most mechanistic insight comes from biochemical/structural studies of protein S domains and from murine genetic models (Section 15).

Suggested ontology terms: GO:0030195 (negative regulation of blood coagulation); GO:0072378 (blood coagulation, fibrin clot formation); GO:0031093 (platelet alpha granule lumen, n/a — not directly relevant); CL:0000182 (hepatocyte, site of synthesis); UBERON:0001997 (vein, site of thrombosis); CHEBI:29108 (calcium ion, cofactor for Gla-domain phospholipid binding, if relevant to a molecular node).

7. Anatomical Structures Affected

Organ/system level: Cardiovascular system — primarily the venous circulation. Primary sites: deep veins of the lower extremities (UBERON:0001474/lower limb vein), pulmonary vasculature (embolic secondary involvement), superficial veins. Less common: cerebral venous sinuses, portal/mesenteric veins, axillary veins. In neonatal purpura fulminans, skin/subcutaneous microvasculature is primarily affected, with potential multi-organ (renal, cerebral, ocular) involvement due to disseminated microthrombosis.
Tissue/cell level: Vascular endothelium (site of anticoagulant cofactor activity), hepatocytes (primary site of protein S synthesis; CL:0000182), platelets (secondary involvement via thrombus formation), dermal/subcutaneous microvasculature (purpura fulminans).
Subcellular level: Not classically compartment-specific for pathology (protein S is a secreted plasma protein); relevant GO Cellular Component for wild-type biology: GO:0005615 (extracellular space), GO:0070062 (extracellular exosome, for some assay contexts).
Localization: Predominantly bilateral or unilateral lower-extremity DVT; PE is typically bilateral/multifocal in the pulmonary vasculature. Purpura fulminans lesions are typically symmetric and affect distal extremities, buttocks, and trunk.

8. Temporal Development

Onset pattern (heterozygous/mild form): Adult-onset, though can occur in adolescence; median age at first VTE reported around 29 years in some cohort analyses; roughly half of carriers become symptomatic before age 55.
Onset pattern (severe homozygous/compound heterozygous form): Neonatal, typically within hours to days of birth (purpura fulminans, massive venous thrombosis, sometimes with evidence of in-utero thrombotic events such as ocular/retinal vessel occlusion).
Progression: Heterozygous disease follows an episodic/recurrent course (discrete VTE events, sometimes provoked, sometimes spontaneous) rather than a steadily progressive one; recurrence is common, especially with inadequate anticoagulation duration or continued risk-factor exposure. The neonatal form is acute and rapidly progressive, requiring emergency plasma-product replacement to prevent death.
Disease course pattern: Relapsing rather than continuously progressive for the common form; post-thrombotic syndrome and chronic venous insufficiency can represent a chronic sequela.
Critical periods / windows of vulnerability: Pregnancy/puerperium (antepartum VTE risk 0.9%, postpartum risk 4.2% in protein S–deficient women — high-risk thrombophilia category), immediate postoperative/post-trauma period, immobilization, initiation of estrogen therapy, and initiation of warfarin without heparin bridging (skin-necrosis window, typically days 3–8 of warfarin therapy based on general VKA-necrosis literature).

9. Inheritance and Population

Epidemiology

Prevalence, partial (heterozygous) deficiency: 0.16–0.21% general population (Orphanet); blood-donor screening estimates 0.03–0.13%.
Prevalence, severe (homozygous/compound heterozygous) deficiency: Unknown precisely, but probably comparable to severe protein C deficiency (~1/500,000) (Orphanet ORPHA:743).
Prevalence among thrombophilia/VTE-referral cohorts: 3–5% (StatPearls); up to 12.7% in Japanese thrombosis patients when the K196E founder variant is included.
Neonatal purpura fulminans (combined protein C + protein S causes): ~1 in 1 million live births.

Inheritance pattern

Autosomal dominant for the common heterozygous/partial deficiency (OMIM #612336, THPH5) — incomplete penetrance (~50%).
Autosomal recessive for the severe homozygous/compound heterozygous form (OMIM #614514, THPH6) — "very rare and severe hematologic disorder resulting in thrombosis and secondary hemorrhage usually beginning in early infancy" (OMIM 614514).

Penetrance / expressivity

Penetrance in heterozygotes ~50% (variable, incomplete).
Expressivity is markedly variable — from asymptomatic carrier status to recurrent life-threatening VTE — modified by co-inherited thrombophilic factors (see below), hormonal exposures, and other acquired risk factors.

Genetic anticipation / germline mosaicism

No genetic-anticipation phenomenon is described (not a repeat-expansion disorder).
Germline mosaicism has been reported: "First report of inherited protein S deficiency caused by paternal PROS1 mosaicism" (Haematologica), relevant for recurrence-risk counseling when a de novo–appearing variant is found in an affected child.

Founder effects / population variation

PROS1 K196E (K155E, "PS Tokushima") is a Japan-specific founder variant, absent in Chinese, Korean, and Caucasian populations, accounting for 9–30% of protein S abnormalities detected in Japan.
Protein S deficiency overall is reported to be "5 to 10 times more common in Japanese populations than in whites," with general-population prevalence of 0.48–0.63% in Japan vs. 12.7% in Japanese thrombosis patients (StatPearls).

Consanguinity

Biallelic (severe/recessive) disease is more likely in consanguineous unions, consistent with autosomal recessive inheritance, though this review did not find a dedicated consanguinity-specific epidemiologic study for PROS1.

Sex and demographic distribution

Men demonstrate higher baseline protein S antigen levels than women.
Protein S levels rise with age in women (hormonal influence) but remain relatively stable in men across adulthood — a key pre-analytical consideration for diagnostic interpretation (StatPearls).

Digenic/combined-defect epidemiology (Factor V Leiden + Protein S deficiency)

In sibships segregating both PROS1 deficiency and Factor V Leiden, 80% of individuals carrying both defects were symptomatic, versus a much lower rate with either defect alone (PubMed 9607123).
Mean age at first thrombosis: 18.4 years (combined defect) vs. 32.6 years (single defect) — "significantly lower... thrombosis-free survival time was significantly shorter" (PubMed 8584987).
Among symptomatic PROS1-deficient probands, FVL prevalence was 38% (vs. general-population FVL prevalence of ~3–5% in most European populations), consistent with strong ascertainment/selection and a synergistic "two-hit" thrombosis model (Blood 1998, 150-family study).

10. Diagnostics

Laboratory tests

Free protein S antigen (immunoturbidimetric/ELISA): considered "the most reliable way of diagnosing the deficiency" because it reflects the functionally active, non-C4BP-bound fraction.
Total protein S antigen (ELISA): detects Type I deficiency well but cannot detect Type II or Type III deficiency, since these have normal total antigen.
Functional (clotting-based) protein S activity assay: measures APC-cofactor–dependent prolongation of clotting time; detects all three types but is technically the most failure-prone assay.
Key pre-analytical/assay pitfalls:
Factor V Leiden causes falsely low functional protein S results in older clotting-based assays (interference); newer assays with plasma-dilution protocols mitigate this.
Levels are altered by pregnancy, oral contraceptives/HRT, acute-phase reaction/inflammation, acute thrombosis itself, vitamin K deficiency, warfarin therapy, and liver disease — testing should be deferred to a stable, non-acute, non-anticoagulated, non-pregnant state where possible.
Age- and sex-adjusted reference ranges are essential given the physiologic variation described above.

ISTH diagnostic criteria (2021 SSC recommendations)

Diagnosis requires persistently reduced plasma protein S concentration and/or activity below the reference interval, confirmed on at least two abnormal results obtained ≥4 weeks apart under appropriate testing conditions (i.e., outside acute thrombosis, pregnancy, and anticoagulation) (Marlar et al., J Thromb Haemost 2021).

Genetic testing

PROS1 sequencing (Sanger or NGS-based single-gene test or thrombophilia gene panel) plus deletion/duplication analysis (MLPA or similar) to detect large exonic deletions.
Available as a clinical test via commercial/academic laboratories (e.g., listed in NCBI GTR) and useful for confirming ambiguous phenotypic results, cascade/family testing, and prenatal or newborn diagnosis in families with known severe (biallelic) disease.
The ISTH maintains/has maintained a PROS1 mutation database resource to support variant interpretation.
ACMG/AMP classification: PROS1 variants are curated in ClinVar with standard pathogenic/likely pathogenic/VUS/likely benign/benign tiers; as above, a 2024–2025 reanalysis found a substantial fraction of variants in suspected-deficiency patients were novel or previously unclassified, underscoring ongoing curation need.

Imaging / functional / other studies

Standard VTE-diagnostic imaging applies (compression ultrasonography for DVT, CT pulmonary angiography for PE, MR venography for cerebral venous sinus thrombosis) — these are general VTE-diagnostic tools, not protein S–specific.
No disease-specific biopsy/histopathology test exists; skin biopsy in warfarin-induced necrosis may show microvascular thrombosis with hemorrhagic necrosis, supportive but non-specific.

Differential diagnosis

Antiphospholipid syndrome, antithrombin deficiency, Factor V Leiden/APC resistance, protein C deficiency, prothrombin G20210A mutation, paroxysmal nocturnal hemoglobinuria, and malignancy-associated hypercoagulability — all must be distinguished, and acquired causes of low protein S (pregnancy, vitamin K deficiency, oral contraceptives, hepatic dysfunction, chronic infection) must be excluded before assigning a congenital diagnosis (StatPearls).

Screening

No population-based newborn screening program for protein S deficiency exists; testing is generally targeted (unprovoked/recurrent VTE, VTE at young age or unusual site, strong family history, neonatal purpura fulminans) and cascade family testing is used once a proband's causal variant is identified.

11. Outcome/Prognosis

Heterozygous/mild disease: Generally good prognosis with appropriate anticoagulation; "little evidence suggests that thrombophilia related to protein S deficiency results in a deteriorated prognosis for VTE" compared with VTE from other causes, though recurrence risk and chronic anticoagulation-associated bleeding risk represent ongoing morbidity (StatPearls).
Severe (biallelic) neonatal disease: Poor prognosis without aggressive, sustained replacement therapy; complications of repeated plasma infusion (fluid overload) contribute to a historically high infant mortality rate; long-term outcome data remain limited.
Recurrence: Recurrent VTE and post-thrombotic syndrome (chronic venous insufficiency, pain, edema, skin changes) are the dominant morbidity drivers in surviving heterozygous patients; a documented case series highlights recurrent DVT/PE "despite optimal anticoagulation therapies" (PMC11180491).
Prognostic modifiers: Co-inherited Factor V Leiden substantially worsens prognosis (earlier onset, shorter thrombosis-free interval, higher penetrance — Section 9); pregnancy is a high-risk period (antepartum VTE 0.9%, postpartum 4.2%).
Mortality: Disease-specific population mortality statistics were not identified in the sources reviewed beyond the neonatal-purpura-fulminans context; adult heterozygous disease mortality is primarily related to PE and anticoagulation-related bleeding rather than the deficiency itself.

12. Treatment

Pharmacotherapy (acute/chronic VTE management)

Initial/acute phase: Intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin (LMWH) for a minimum of ~5 days.
Maintenance: Vitamin K antagonist (warfarin) or a direct oral anticoagulant (DOAC, e.g., apixaban, rivaroxaban). DOACs are increasingly favored for efficacy/safety, with warfarin reserved for specific situations (extremes of body weight, large proximal clot burden, massive/submassive PE) — suggest NCIT:C15986 (Pharmacotherapy) as treatment_term with therapeutic_agent bound to CHEBI (e.g., warfarin CHEBI:10033, apixaban CHEBI:66401) or NCIT drug terms.
Duration: Standard 3–6 months post-VTE; extended/lifelong anticoagulation for life-threatening events, unusual/multiple-site thrombosis, or recurrent unprovoked VTE; shorter courses acceptable when a strong transient provoking factor (surgery/trauma) was present without unusual features.
Warfarin-necrosis avoidance: Heparin bridging during warfarin initiation is critical in protein C/S–deficient patients to avoid the transient hypercoagulable "warfarin necrosis" window; if necrosis occurs, heparin is reinstituted and warfarin may be cautiously restarted at low dose with overlap once the acute event resolves (PubMed 1427456).

Advanced/replacement therapeutics (severe congenital form)

Fresh frozen plasma (FFP): first-line emergency replacement therapy for neonatal purpura fulminans, typically dosed every 8–12 hours and titrated to clinical response.
Plasma-derived protein C/protein S concentrate: an emerging, more targeted replacement option available at some centers, though access remains limited (NORD/GARD; StatPearls).
Liver transplantation has been used as definitive therapy for severe homozygous protein C deficiency (analogous rationale could extend to protein S, though this review found the direct evidence base specifically for protein S transplantation to be sparse — flagged as a gap).

Surgical/interventional

No protein S–deficiency–specific surgical intervention; standard VTE-related interventions (IVC filter in select cases, thrombectomy for massive PE/limb-threatening DVT) apply per general VTE guidelines.

Supportive/rehabilitative

Compression therapy for post-thrombotic syndrome, physical therapy/mobility rehabilitation, and wound care for purpura fulminans/skin necrosis lesions.

Pregnancy-specific management

LMWH is preferred throughout pregnancy (does not cross the placenta); warfarin is contraindicated for teratogenicity; specific caution is advised in the first trimester and after 36 weeks gestation, transitioning to LMWH over warfarin in those windows to minimize fetal/maternal bleeding risk. Protein S deficiency is classified as a high-risk thrombophilia in pregnancy risk-stratification schemes.

Prophylaxis in asymptomatic carriers

Risk-adapted prophylactic anticoagulation is recommended around known high-risk exposures (surgery, prolonged immobilization, long-haul travel, pregnancy) rather than universal indefinite anticoagulation for asymptomatic carriers.

Experimental/trial landscape

The literature surveyed did not identify active gene-therapy, RNA-based, or novel targeted-biologic trials specific to protein S deficiency (unlike, e.g., hemophilia); management remains centered on conventional and plasma-derived anticoagulant/replacement approaches. (This is a notable gap suitable for just verify-datasets/ClinicalTrials.gov confirmation before KB citation.)

Treatment outcomes / adverse events

Standard anticoagulant bleeding risk applies; cumulative bleeding risk increases with extended/lifelong therapy duration.
Warfarin-induced skin necrosis is an uncommon but serious adverse event more classically linked to protein C deficiency, with rare case reports in protein S deficiency.

13. Prevention

Primary prevention: Avoidance of estrogen-containing contraceptives/HRT in known carriers; prophylactic anticoagulation around high-risk exposures (surgery, immobilization, pregnancy, travel).
Secondary prevention: Prompt recognition and treatment of first VTE event to reduce recurrence and post-thrombotic syndrome; screening of family members of an index case via cascade testing.
Tertiary prevention: Extended-duration anticoagulation in patients with life-threatening or recurrent/unusual-site thrombosis to prevent further events; compression therapy to limit post-thrombotic syndrome progression.
Genetic/prenatal counseling: Recommended for families with known severe (biallelic) disease, particularly given documented germline mosaicism and the life-threatening neonatal phenotype; carrier and prenatal testing can be offered in high-risk families once the familial PROS1 variant(s) are characterized.
Screening: No population-based newborn screening program exists; targeted screening is triggered by unprovoked or recurrent VTE at a young age, VTE at an unusual site, strong family history, or neonatal purpura fulminans.
Public health/behavioral: General VTE risk-reduction counseling (mobility, hydration during travel, smoking cessation given compounding vascular risk) applies but is not disease-specific.

14. Other Species / Natural Disease

No naturally occurring (spontaneous) animal model of protein S deficiency analogous to human PROS1 disease was identified in this review; by contrast, congenital protein C deficiency has been reported in a dog (PMC7255666), but an equivalent natural canine/feline protein S deficiency case was not found in the sources searched (OMIA-style entries for this specific condition were not located). This is a notable evidence gap — absence of identified reports, not confirmed absence of the condition in veterinary species.
Orthologous gene: Pros1 is conserved across mammals (mouse Pros1, NCBI Gene); no cross-species comparative pathology literature specific to naturally occurring disease was found.
Zoonotic potential: Not applicable — this is a non-infectious, genetic/acquired hemostatic disorder.

15. Model Organisms

Global Pros1 knockout mice: Complete (germline) Pros1 knockout is embryonic lethal, causing a coagulopathy and vascular dysgenesis phenotype — "Lack of Protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis" (JCI), directly paralleling the severe consequences of near-total human protein S loss (as in neonatal purpura fulminans) and confirming an essential, non-redundant role for protein S in vascular/hemostatic development.
Conditional (floxed) Pros1 knockout mice: Because global knockout is lethal, researchers generated a Cre-lox conditional floxed Pros1 allele and crossed it with multiple Cre-driver lines to achieve tissue-specific inactivation — pan-cellular, hepatocyte-specific, endothelial/hematopoietic-specific, and vascular smooth muscle cell (VSMC)-specific knockouts — revealing "dramatic but divergent phenotypes" across tissue compartments and clarifying the relative contributions of different cellular sources of protein S, analyzed alongside the related Axl/Gas6 receptor-ligand knockout mice (protein S's paralog Gas6 signals through the TAM receptor family, of which protein S itself also weakly engages Tyro3).
PS K196E (Tokushima) knock-in mouse: A mouse model carrying the human K196E mutation showed "exacerbated venous thromboembolism," directly demonstrating causality of this Japan-specific variant for thrombotic risk in vivo (Blood 2015) and confirming that the mutation "reduces its cofactor activity for APC but not for TFPI" — a mechanistically informative dissociation between the two protein S anticoagulant functions (PMC6178719).
Applications: These murine models have been central to establishing (a) the non-redundant, developmentally essential role of protein S in vascular integrity, (b) tissue-specific sourcing of functionally relevant plasma protein S, and (c) the mechanistic basis (APC- vs. TFPI-cofactor–selective loss) of specific human missense variants.
Limitations: Complete knockout lethality means no adult "null" mouse model exists for studying postnatal severe deficiency physiology directly; conditional models are needed, and cross-species differences in coagulation-factor regulation (e.g., mouse vs. human C4BP stoichiometry) may limit direct translational extrapolation.
Resources: MGI (Mouse Genome Informatics) carries the Pros1 gene and knockout allele records; IMPC/KOMP repositories may hold additional conditional-allele strains (not individually itemized in the sources retrieved here).

Summary of Key Evidence Gaps (flagged for curation)

No naturally occurring veterinary (dog/cat) model of protein S deficiency was located, despite a documented canine protein C deficiency case — worth a targeted OMIA search before asserting absence.
Disease-specific quality-of-life instrument data (EQ-5D/SF-36) specific to protein S deficiency were not found; QOL impact is inferred from general VTE/anticoagulation morbidity literature.
Active gene-therapy/RNA-therapeutic clinical trials specific to protein S deficiency were not identified — the therapeutic landscape remains conventional (anticoagulant/plasma replacement).
Precise disease-specific mortality/life-expectancy statistics (beyond neonatal purpura fulminans mortality risk) were not found in a single aggregated source; figures cited (e.g., annual VTE incidence 1.90%, median onset age 29) trace to StatPearls' synthesis rather than a single primary epidemiologic study, and should be traced to primary cohort sources before KB citation.
Liver transplantation as definitive therapy is documented for homozygous protein C deficiency; direct primary-literature support for protein S–specific transplantation outcomes was not retrieved and should not be assumed by analogy without confirmation.